Barrick stock rises after report of Newmont eyeing Nevada gold assets
Investing.com -- AbbVie (NYSE:ABBV) stock rose over 3% after the company announced it has settled litigation with all generic manufacturers that filed applications for generic versions of its RINVOQ medication, securing patent protection until 2037.
The settlement and license agreements, announced on September 11, 2025, ensure that no generic version of upadacitinib tablets (marketed as RINVOQ) will enter the U.S. market before April 2037, assuming pediatric exclusivity is granted. These agreements are subject to standard acceleration provisions.
This development represents a significant extension of market exclusivity for one of AbbVie’s key products. The settlement provides AbbVie with approximately five additional years of patent protection beyond what analysts had previously anticipated.
Wells Fargo analyst Mohit Bansal described the settlement as a "big win" for AbbVie, noting that consensus estimates had previously modeled patent expiry in 2032. Bansal estimates the extended protection could add between $11 to $24 per share in discounted cash flow value.
The analyst also suggested that AbbVie’s other major drug, Skyrizi, could potentially secure a similar settlement, further strengthening the company’s long-term outlook. Bansal added that AbbVie represents a unique investment opportunity in the pharmaceutical sector due to its extended growth runway.
RINVOQ is one of AbbVie’s key immunology products and has been approved for multiple inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.